Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006)

被引:60
作者
Beutels, Philippe
Thiry, Nancy
Van Damme, Pierre
机构
[1] Univ Antwerp VIB, Ctr Evaluat Vaccinat Epidemiol & Social Med, B-2610 Antwerp, Belgium
[2] Univ Sydney, Sch Publ Hlth, NCIRS, Sydney, NSW 2006, Australia
关键词
cost-effectiveness vaccination; economic; pneumococcal; herd immunity;
D O I
10.1016/j.vaccine.2006.10.034
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over EURO 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1355 / 1367
页数:13
相关论文
共 41 条
  • [11] Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
    Bos, JM
    Rümke, H
    Welte, R
    Postma, MJ
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (10) : 2614 - 2630
  • [12] Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany
    Claes, C
    von der Schulenburg, JMG
    [J]. PHARMACOECONOMICS, 2003, 21 (08) : 587 - 600
  • [13] Economic aspects of pneumococcal pneumonia - A review of the literature
    De Graeve, D
    Beutels, P
    [J]. PHARMACOECONOMICS, 2004, 22 (11) : 719 - 740
  • [14] Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada
    De Wals, P
    Petit, G
    Erickson, LJ
    Guay, M
    Tam, T
    Law, B
    Framarin, A
    [J]. VACCINE, 2003, 21 (25-26) : 3757 - 3764
  • [15] Drummond M., 2015, METHODS EC EVALUATIO, V4
  • [16] Efficacy of a pneumococcal conjugate vaccine against acute otitis media
    Eskola, J
    Kilpi, T
    Palmu, A
    Jokinen, J
    Haapakoski, J
    Herva, E
    Takala, A
    Käyhty, H
    Karma, P
    Kohberger, R
    Siber, G
    Mäkela, PH
    Lockhart, S
    Ecrola, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) : 403 - 409
  • [17] Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants
    Esposito, S
    Pugni, L
    Bosis, S
    Proto, A
    Cesati, L
    Bianchi, C
    Cimino, C
    Mosca, F
    Principi, N
    [J]. VACCINE, 2005, 23 (14) : 1703 - 1708
  • [18] Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland
    Ess, SM
    Schaad, UB
    Gervaix, A
    Pinösch, S
    Szucs, TD
    [J]. VACCINE, 2003, 21 (23) : 3273 - 3281
  • [19] Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization
    Flannery, B
    Heffernan, RT
    Harrison, LH
    Ray, SM
    Reingold, AL
    Hadler, J
    Schaffner, W
    Lynfield, R
    Thomas, AR
    Li, JM
    Campsmith, M
    Whitney, CG
    Schuchat, A
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 144 (01) : 1 - 9
  • [20] FORD M, 2004, J MED EC, V7, P85